...
首页> 外文期刊>Liver international : >Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.
【24h】

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

机译:肝细胞癌的预后指标:对72项研究的系统评价。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Although there are many studies of the predictors of death in hepatocellular carcinoma (HCC), most combine patients with and without cirrhosis and many combine those with compensated and decompensated cirrhosis. OBJECTIVE: To perform a systematic review of the literature evaluating the predictors of death in patients with cirrhosis and HCC and to evaluate whether the predictors differ between patients with compensated and decompensated cirrhosis. METHODS: Inclusion criteria: (i) publication in English, (ii) adult patients, (c) >80% of the patients had cirrhosis, (iv) follow-up >6 months and (v) multivariable analysis. Quality was based on the accepted quality criteria for prognostic studies. RESULTS: Of the 1106 references obtained, 947 were excluded because they did not meet the inclusion criteria. A total of 23 968 patients were included in 72 studies (median, 177/study); 77% male, median age 64, 55% Child-Pugh class A. The most robust predictors of death were portal vein thrombosis, tumour size, alpha-foetoprotein and Child-Pugh class. Sensitivity analysis using only 15 'good' studies and 22 studies in which all patients had cirrhosis yielded the same variables. In the studies including mostly compensated or decompensated patients, the predictors were both liver and tumour related. However, these studies were few and the results were not robust. CONCLUSIONS: This systematic review of 72 studies shows that the most robust predictors of death in patients with cirrhosis and HCC are tumour related and liver related. Future prognostic studies should include these predictors and should be performed in specific patient populations to determine whether specific prognostic indicators are more relevant at different stages of cirrhosis.
机译:背景:尽管有许多关于肝细胞癌(HCC)死亡预测因素的研究,但大多数合并有或没有肝硬化的患者,而许多合并有代偿性和代偿性肝硬化的患者。目的:对文献进行系统评价,以评估肝硬化和肝癌患者死亡的预测因素,并评估代偿性和失代偿性肝硬化患者之间的预测因素是否不同。方法:纳入标准:(i)以英文发表,(ii)成年患者,(c)超过80%的患者患有肝硬化,(iv)随访> 6个月,(v)多变量分析。质量基于用于预后研究的公认质量标准。结果:在获得的1106份参考文献中,有947份被排除在外,因为它们不符合纳入标准。 72项研究共纳入23968例患者(中位值为177 /研究)。男性占77%,中位年龄64岁,占A级Child-Pugh的55%。死亡的最有力预测指标是门静脉血栓形成,肿瘤大小,α-甲胎蛋白和Child-Pugh级。仅使用15项“良好”研究和22项所有肝硬化患者的敏感性分析得出相同的变量。在包括多数代偿或代偿失调患者的研究中,预测因素与肝脏和肿瘤有关。但是,这些研究很少,结果也不可靠。结论:这项对72项研究的系统评价表明,肝硬化和HCC患者死亡的最强有力的预测因子与肿瘤有关,而与肝有关。未来的预后研究应包括这些预测因素,并应在特定的患者人群中进行,以确定特定的预后指标在肝硬化的不同阶段是否更相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号